It’s no secret that the COVID-19 pandemic was a massive driver of demand for laboratory, incubator and biomanufacturing space from life sciences companies and real estate investors alike.
The sector’s unique characteristic — vital research cannot be conducted anywhere except in a lab — gave it the ability to circumvent lockdown and work-from-home mandates, fueling investor confidence in the resilience of demand for these types of facilities...
RSK: When you go from 0-80 in a few months then slow down to 70....it`s not exactly a major drop. Life science sector is doing just fine.
- - Volume: 10 - WEEK: 33 Date: 8/9/2022 10:10:57 AM -